Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cellectis

- PMLiVE

Major depression in UK cancer patients going untreated

Only 17% of patients reacted to usual NHS therapy according to new research

- PMLiVE

Merck and Advaxis to study anti-PD1 combo

Collaboration to investigate pembrolizumab and ADXS-PSA in prostate cancer

- PMLiVE

AZ launches DoctorsNotes online medical literature tool

New browser extension aims to make HCP's reading 'shareable and social'

- PMLiVE

Illumina partners with pharma majors on cancer diagnostic

Will work with AstraZeneca, Janssen and Sanofi to develop gene sequencing tool

- PMLiVE

Brilinta bill of health boosts AstraZeneca

US drops investigation into study data

- PMLiVE

AstraZeneca launches diabetes portal in Germany

Zuckerkrank.de is designed to educate patients and families

- PMLiVE

AZ takes asthma antibody into phase III

Tralokinumab tipped as potential blockbuster

- PMLiVE

Phase III data back AZ’s gout drug

Lesinurad on course to be filed this year

- PMLiVE

AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

Will boost its pipeline prospects and inhaled device capabilities

- PMLiVE

AZ signs two companion diagnostic deals

Will help identify patients suitable for treatment with lung cancer drugs

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

- PMLiVE

Nexavar fails late-stage breast cancer trial

Bayer’s oncology drug unable to improve progression free survival in new indication

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links